Total Payments
$4,200
2024 Payments
$1,467
Companies
43
Transactions
93
Medicare Patients
3,177
Medicare Billing
$532,772
Payment Breakdown by Category
Food & Beverage$2,795 (66.6%)
Consulting$1,249 (29.7%)
Education$155.91 (3.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,795 | 89 | 66.6% |
| Consulting Fee | $1,249 | 1 | 29.7% |
| Education | $155.91 | 3 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $1,437 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $372.74 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $193.76 | 3 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $178.98 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $152.40 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $139.64 | 2 | $0 (2024) |
| PFIZER INC. | $120.00 | 2 | $0 (2024) |
| Kite Pharma, Inc. | $114.33 | 1 | $0 (2018) |
| Exelixis Inc. | $111.10 | 3 | $0 (2022) |
| ABBVIE INC. | $110.63 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,467 | 56 | Takeda Pharmaceuticals U.S.A., Inc. ($140.76) |
| 2023 | $378.28 | 17 | Daiichi Sankyo Inc. ($72.71) |
| 2022 | $1,290 | 2 | Daiichi Sankyo Inc. ($1,249) |
| 2020 | $77.68 | 2 | AstraZeneca Pharmaceuticals LP ($52.96) |
| 2019 | $429.79 | 8 | E.R. Squibb & Sons, L.L.C. ($125.00) |
| 2018 | $457.30 | 7 | AstraZeneca Pharmaceuticals LP ($127.70) |
| 2017 | $100.00 | 1 | Janssen Biotech, Inc. ($100.00) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Oncology | ||||||
| 12/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Oncology | ||||||
| 12/17/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.98 | General |
| Category: Hematology | ||||||
| 11/20/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: BioOncology | ||||||
| 11/06/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $27.81 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $63.10 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.15 | General |
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.44 | General |
| 10/21/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $37.24 | General |
| 10/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.89 | General |
| 10/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Immunology | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $34.09 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Oncology | ||||||
| 09/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: BioOncology | ||||||
| 08/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 264 | 587 | $140,000 | $31,002 |
| 2022 | 18 | 723 | 2,265 | $247,420 | $56,261 |
| 2021 | 21 | 1,031 | 48,398 | $798,700 | $156,918 |
| 2020 | 29 | 1,159 | 56,838 | $1.6M | $288,590 |
Total Patients
3,177
Total Services
108,088
Medicare Billing
$532,772
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 157 | 437 | $93,081 | $20,729 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 84 | $26,376 | $6,074 | 23.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $13,068 | $2,688 | 20.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $4,121 | $821.92 | 19.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 26 | $3,354 | $689.25 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 169 | 520 | $110,760 | $26,966 | 24.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 18 | 72 | $30,312 | $7,100 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 45 | 90 | $28,260 | $7,015 | 24.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 168 | 377 | $13,195 | $2,910 | 22.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 19 | $7,600 | $1,974 | 26.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 19 | 30 | $6,600 | $1,489 | 22.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 19 | 123 | $8,364 | $1,457 | 17.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $5,808 | $1,372 | 23.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $6,657 | $1,203 | 18.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 20 | $4,200 | $1,093 | 26.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2022 | 11 | 45 | $7,830 | $1,073 | 13.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 26 | 89 | $6,497 | $919.08 | 14.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 129 | 197 | $4,531 | $588.06 | 13.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2022 | 12 | 57 | $2,622 | $527.90 | 20.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 13 | $1,677 | $413.19 | 24.6% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2022 | 12 | 51 | $408.00 | $102.02 | 25.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 512 | $2,048 | $46.47 | 2.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 11 | 17 | $51.00 | $12.50 | 24.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2021 | 28 | 42,000 | $220,920 | $37,595 | 17.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 18 | 2,280 | $173,280 | $37,214 | 21.5% |
About Dr. Ali Sayed, MD
Dr. Ali Sayed, MD is a Hematology & Oncology healthcare provider based in Athens, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2008. The National Provider Identifier (NPI) number assigned to this provider is 1548410400.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ali Sayed, MD has received a total of $4,200 in payments from pharmaceutical and medical device companies, with $1,467 received in 2024. These payments were reported across 93 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($2,795).
As a Medicare-enrolled provider, Sayed has provided services to 3,177 Medicare beneficiaries, totaling 108,088 services with total Medicare billing of $532,772. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Athens, GA
- Active Since 09/26/2008
- Last Updated 11/09/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548410400
Products in Payments
- ENHERTU (Drug) $1,249
- ERLEADA (Drug) $203.43
- IMBRUVICA (Drug) $180.82
- TAGRISSO (Drug) $180.66
- KEYTRUDA (Biological) $152.40
- Enhertu (Drug) $133.78
- OPDIVO (Biological) $125.00
- DARZALEX (Biological) $122.20
- Yescarta (Drug) $114.33
- TALZENNA (Drug) $99.70
- LifeVest (Device) $87.01
- Cabometyx (Drug) $86.38
- Sylvant (Biological) $60.06
- KISQALI (Drug) $55.31
- Orserdu (Drug) $54.64
- NINLARO (Drug) $53.00
- VENCLEXTA (Drug) $52.91
- ULTOMIRIS (Biological) $50.56
- FRUZAQLA (Drug) $46.03
- LIBTAYO (Biological) $45.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Athens
Dr. Priya Rudolph, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $666,297
Hematology & Oncology $666,297
Amanda Hathaway, M.d, M.D
Hematology & Oncology — Payments: $147,716
Hematology & Oncology $147,716
Dr. Charles Bodine, M.d, M.D
Hematology & Oncology — Payments: $9,979
Hematology & Oncology $9,979
Dr. Frederick Flynt, M.d, M.D
Hematology & Oncology — Payments: $9,466
Hematology & Oncology $9,466
Shawn Tai, M.d, M.D
Hematology & Oncology — Payments: $9,190
Hematology & Oncology $9,190
Ms. Addie Hill, M.d, M.D
Hematology & Oncology — Payments: $5,608
Hematology & Oncology $5,608